IL326294A - Apilimod compositions and methods of use - Google Patents

Apilimod compositions and methods of use

Info

Publication number
IL326294A
IL326294A IL326294A IL32629426A IL326294A IL 326294 A IL326294 A IL 326294A IL 326294 A IL326294 A IL 326294A IL 32629426 A IL32629426 A IL 32629426A IL 326294 A IL326294 A IL 326294A
Authority
IL
Israel
Prior art keywords
methods
apilimod
compositions
apilimod compositions
Prior art date
Application number
IL326294A
Other languages
Hebrew (he)
Original Assignee
Orphai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/230,099 external-priority patent/US12589097B2/en
Application filed by Orphai Therapeutics Inc filed Critical Orphai Therapeutics Inc
Publication of IL326294A publication Critical patent/IL326294A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
IL326294A 2023-08-03 2024-08-01 Apilimod compositions and methods of use IL326294A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/230,099 US12589097B2 (en) 2018-02-21 2023-08-03 Apilimod compositions and methods of use
PCT/US2024/040574 WO2025030033A1 (en) 2023-08-03 2024-08-01 Apilimod compositions and methods of use

Publications (1)

Publication Number Publication Date
IL326294A true IL326294A (en) 2026-04-01

Family

ID=94396049

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326294A IL326294A (en) 2023-08-03 2024-08-01 Apilimod compositions and methods of use

Country Status (5)

Country Link
KR (1) KR20260048558A (en)
CN (1) CN121666238A (en)
AU (1) AU2024316559A1 (en)
IL (1) IL326294A (en)
WO (1) WO2025030033A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758545B2 (en) * 2015-06-25 2020-09-01 University Of Southern California Methods to treat neurological diseases
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
EP4351585A1 (en) * 2021-06-11 2024-04-17 Orphai Therapeutics Inc. Stabilized apilimod compositions and uses thereof

Also Published As

Publication number Publication date
CN121666238A (en) 2026-03-13
KR20260048558A (en) 2026-04-10
AU2024316559A1 (en) 2026-02-26
WO2025030033A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
IL309073A (en) Enantiomeric entactogen compositions and methods of their use
IL308041A (en) Collagen compositions and methods of use thereof
PT4267105T (en) Antibody compositions and methods of use thereof
GB2622995B (en) CAS13-based compositions and methods of use thereof
IL312928A (en) Complement factor b-modulating compositions and methods of use thereof
EP4204004A4 (en) Anti-idiotype compositions and methods of use thereof
IL316049A (en) Pharmaceutical compositions of mosunetuzumab and methods of use
EP4381022A4 (en) Compositions and methods of use thereof
IL315862A (en) Angiotensinogen-modulating compositions and methods of use thereof
EP4298076A4 (en) Ceramic compositions and methods of use
IL314226A (en) Designed cytokine compositions and methods of use
IL325628A (en) Coagulation factor xi-modulating compositions and methods of use thereof
IL321134A (en) Olanzapine compositions and methods of use
IL325816A (en) Endoxifen compositions and methods of use thereof and synthesis thereof
IL326294A (en) Apilimod compositions and methods of use
GB202313643D0 (en) Serping1-sarna compositions and methods of use
GB202310868D0 (en) compositions and methods of use
IL325884A (en) Gal475 compositions and methods of use thereof
IL311518A (en) Prekallikrein-modulating compositions and methods of use thereof
CA3298683A1 (en) Apilimod compositions and methods of use
CA3292256A1 (en) Sleep-improving compositions and methods of use
GB202318443D0 (en) Compositions and methods of treatment
CA3298694A1 (en) Gal475 compositions and methods of use thereof
GB202405768D0 (en) Compositions and uses of oligo-chromopeptides and methods of making
CA3296452A1 (en) Lrrk2-modulating compositions and methods of use thereof